Kazuya Kobayashi
Kyoto Pharmaceutical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kazuya Kobayashi.
Bioorganic & Medicinal Chemistry Letters | 2014
Hiroyuki Konno; Hitoshi Endo; Satomi Ise; Keiki Miyazaki; Hideo Aoki; Akira Sanjoh; Kazuya Kobayashi; Yasunao Hattori; Kenichi Akaji
To research a new non-peptidyl inhibitor of beta-site amyloid precursor protein cleaving enzyme 1, we focused on the curcumin framework, two phenolic groups combined with an sp2 carbon spacer for low-molecular and high lipophilicity. The structure-activity relationship study of curcumin derivatives is described. Our results indicate that phenolic hydroxy groups and an alkenyl spacer are important structural factors for the inhibition of beta-site amyloid precursor protein cleaving enzyme 1 and, furthermore, non-competitive inhibition of enzyme activity is anticipated from an inhibitory kinetics experiment and docking simulation.
Bioorganic & Medicinal Chemistry | 2015
Yasuhiro Shimamoto; Yasunao Hattori; Kazuya Kobayashi; Kenta Teruya; Akira Sanjoh; Atsushi Nakagawa; Eiki Yamashita; Kenichi Akaji
n Abstractn n The design and evaluation of a novel decahydroisoquinolin scaffold as an inhibitor for severe acute respiratory syndrome (SARS) chymotrypsin-like protease (3CLpro) are described. Focusing on hydrophobic interactions at the S2 site, the decahydroisoquinolin scaffold was designed by connecting the P2 site cyclohexyl group of the substrate-based inhibitor to the main-chain at the α-nitrogen atom of the P2 position via a methylene linker. Starting from a cyclohexene enantiomer obtained by salt resolution, trans-decahydroisoquinolin derivatives were synthesized. All decahydroisoquinolin inhibitors synthesized showed moderate but clear inhibitory activities for SARS 3CLpro, which confirmed the fused ring structure of the decahydroisoquinolin functions as a novel scaffold for SARS 3CLpro inhibitor. X-ray crystallographic analyses of the SARS 3CLpro in a complex with the decahydroisoquinolin inhibitor revealed the expected interactions at the S1 and S2 sites, as well as additional interactions at the N-substituent of the inhibitor.n n
Biochimica et Biophysica Acta | 2014
Maria Hayashi; Kazuya Kobayashi; Hiroyoshi Esaki; Hiroyuki Konno; Kenichi Akaji; Keiko Tazuya; Kazuko Yamada; Toshikatsu Nakabayashi; Kazuto Nosaka
Studies on thiamin biosynthesis have so far been achieved in eubacteria, yeast and plants, in which the thiamin structure is formed as thiamin phosphate from a thiazole and a pyrimidine moiety. This condensation reaction is catalyzed by thiamin phosphate synthase, which is encoded by the thiE gene or its orthologs. On the other hand, most archaea do not seem to have the thiE gene, but instead their thiD gene, coding for a 2-methyl-4-amino-5-hydroxymethylpyrimidine (HMP) kinase/HMP phosphate kinase, possesses an additional C-terminal domain designated thiN. These two proteins, ThiE and ThiN, do not share sequence similarity. In this study, using recombinant protein from the hyperthermophile archaea Pyrobaculum calidifontis, we demonstrated that the ThiN protein is an analog of the ThiE protein, catalyzing the formation of thiamin phosphate with the release of inorganic pyrophosphate from HMP pyrophosphate and 4-methyl-5-β-hydroxyethylthiazole phosphate (HET-P). In addition, we found that the ThiN protein can liberate an inorganic pyrophosphate from HMP pyrophosphate in the absence of HET-P. A structure model of the enzyme-product complex of P. calidifontis ThiN domain was proposed on the basis of the known three-dimensional structure of the ortholog of Pyrococcus furiosus. The significance of Arg320 and His341 residues for thiN-coded thiamin phosphate synthase activity was confirmed by site-directed mutagenesis. This is the first report of the experimental analysis of an archaeal thiamin synthesis enzyme.
Biochemical and Biophysical Research Communications | 2015
Yuki Toda; Kazuyuki Takata; Yuko Nakagawa; Hikaru Kawakami; Shusuke Fujioka; Kazuya Kobayashi; Yasunao Hattori; Yoshihisa Kitamura; Kenichi Akaji; Eishi Ashihara
Exosomes, the natural vehicles of various biological molecules, have been examined in several research fields including drug delivery. Although understanding of the biological functions of exosomes has increased, how exosomes are transported between cells remains unclear. We hypothesized that cell tropism is important for effective exosomal intercellular communication and that parental cells regulate exosome movement by modulating constituent exosomal molecules. Herein, we demonstrated the strong translocation of glioblastoma-derived exosomes (U251exo) into their parental (U251) cells, breast cancer (MDA-MB-231) cells, and fibrosarcoma (HT-1080). Furthermore, disruption of proteins of U251exo by enzymatic treatment did not affect their uptake. Therefore, we focused on lipid molecules of U251exo with the expectation that they are crucial for effective incorporation of U251exo by cancer cells. Phosphatidylethanolamine was identified as a unique lipid component of U251-MG cell-derived extracellular vesicles. From these results, valuable insight is provided into the targeting of U251exo to cancer cells, which will help to develop a cancer-targeted drug delivery system.
Heterocycles | 2015
Yasunao Hattori; Masatomo Katsuyama; Masahiro Furuta; Kazuya Kobayashi; Kenta Teruya; Hidefumi Makabe; Kenichi Akaji
Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan; Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-cho, Sakyo-ku, Kyoto 606-0823, Japan; Graduate School of Agriculture, Sciences of Functional Foods, Shinshu University, 8304 Minamiminowa, Kami-ina, Nagano 399-4598, Japan; E-mail: [email protected]
Bioorganic & Medicinal Chemistry | 2015
Yasunao Hattori; Kazuya Kobayashi; Ayaka Deguchi; Yukie Nohara; Tomomi Akiyama; Kenta Teruya; Akira Sanjoh; Atsushi Nakagawa; Eiki Yamashita; Kenichi Akaji
A superior substrate sequence for BACE1 containing transition-state mimics at the scissile site was evaluated as a protease inhibitor. Hydroxymethylcarbonyl (HMC) and hydroxyethylamine (HEA) isosteres were selected as the transition state mimics, and incorporated into the scissile site of the superior sequence covering the P4 to P1 sites (Glu-Ile-Thi-Thi(*)Nva; (*)denotes the cleavage site). Isosteres having different absolute configurations of the hydroxyl group were synthesized separately, and the effect of the configuration was evaluated. Configuration of the hydroxyl group of each isostere showed a marked effect on the inhibitory activity; anti-configuration to the scissile site substituent had potent inhibitory activity in an HMC-type inhibitor, whereas anti-configuration of HEA-type inhibitors showed no inhibitory activity. Structural evaluations based on X-ray crystallographic analyses of recombinant BACE1 in complex with each inhibitor provided insights into the protein-ligand interactions, especially at the prime sites.
Journal of Medicinal Chemistry | 2018
Haruka Sekiguchi; Tomoko Kuroyanagi; David Rhainds; Kazuya Kobayashi; Yuka Kobayashi; Hiroaki Ohno; Nikolaus Heveker; Kenichi Akaji; Nobutaka Fujii; Shinya Oishi
The atypical chemokine receptor 3 (ACKR3)/CXC chemokine receptor 7 (CXCR7) recognizes stromal cell-derived factor 1 (SDF-1)/CXCL12 and is involved in a number of physiological and pathological processes. Here, we investigated the SAR of the component amino acids in an ACKR3-selective ligand, FC313 [ cyclo(-d-Tyr-l-Arg-l-MeArg-l-Nal(2)-l-Pro-)], for the development of highly active ACKR3 ligands. Notably, modification at the l-Pro position with a bulky hydrophobic side chain led to improved bioactivity toward ACKR3.
Biopolymers | 2016
Kenta Teruya; Yasunao Hattori; Yasuhiro Shimamoto; Kazuya Kobayashi; Akira Sanjoh; Atsushi Nakagawa; Eiki Yamashita; Kenichi Akaji
Design of inhibitors against severe acute respiratory syndrome (SARS) chymotrypsin‐like protease (3CLpro) is a potentially important approach to fight against SARS. We have developed several synthetic inhibitors by structure‐based drug design. In this report, we reveal two crystal structures of SARS 3CLpro complexed with two new inhibitors based on our previous work. These structures combined with six crystal structures complexed with a series of related ligands reported by us are collectively analyzed. To these eight complexes, the structural basis for inhibitor binding was analyzed by the COMBINE method, which is a chemometrical analysis optimized for the protein–ligand complex. The analysis revealed that the first two latent variables gave a cumulative contribution ratio of r2u2009=u20090.971. Interestingly, scores using the second latent variables for each complex were strongly correlated with root mean square deviations (RMSDs) of side‐chain heavy atoms of Met49 from those of the intact crystal structure of SARS‐3CLpro (ru2009=u20090.77) enlarging the S2 pocket. The substantial contribution of this side chain (∼10%) for the explanation of pIC50s was dependent on stereochemistry and the chemical structure of the ligand adapted to the S2 pocket of the protease. Thus, starting from a substrate mimic inhibitor, a design for a central scaffold for a low molecular weight inhibitor was evaluated to develop a further potent inhibitor.
Bioorganic & Medicinal Chemistry | 2014
Chiyuki Awahara; Tadashi Tatsumi; Saki Furuta; Gen Shinjoh; Hiroyuki Konno; Kazuto Nosaka; Kazuya Kobayashi; Yasunao Hattori; Kenichi Akaji
The effects of additional substituents covering the prime-site of retro-inverso (RI)-modified HTLV-1 protease inhibitors containing a hydroxyethylamine isoster were clarified. Stereo-selective construction of the most potent isoster backbone was achieved by the Evans-aldol reaction. Addition of N-acetylated d-amino acid corresponding to the P2 site gave an RI-modified inhibitor showing superior inhibitory activity to the previous inhibitor. Inhibitory activities of the newly synthesized inhibitors suggest that partially modified RI inhibitors would interact with HTLV-1 protease in the same manner as the parent hydroxyethylamine inhibitor.
Inorganic Chemistry | 2018
Yuka Kobayashi; Masaru Hoshino; Tomoshi Kameda; Kazuya Kobayashi; Kenichi Akaji; Shinsuke Inuki; Hiroaki Ohno; Shinya Oishi
Fe(II)-coordinating hexapeptides containing three 2,2-bipyridine moieties as side chains were designed and synthesized. A cyclic hexapeptide having three [(2,2-bipyridin)-5-yl]-d-alanine (d-Bpa5) residues, in which d-Bpa5 and Gly are alternately arranged with 3-fold rotational symmetry, coordinated with Fe(II) to form a 1:1 octahedral Fe(II)-peptide complex with a single facial-Λ configuration of the metal-centered chirality. NMR spectroscopy and molecular dynamics simulations revealed that the Fe(II)-peptide complex has an apparent C3-symmetric conformations on the NMR time scale, while the peptide backbone is subject to dynamic conformational exchange between three asymmetric β/γ conformations and one C3-symmetric γ/γ/γ conformation. The semirigid cyclic hexapeptide preferentially arranged these conformations of the small octahedral Fe(II)-bipyridine complex, as well as the Ru(II) congener, to underpin the single configuration of the metal-centered chirality.